Having trouble viewing this email? View in your browser.
ESCMID Logo

26 March 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

Registration for ECCMID 2019

ECCMID is approaching soon in Amsterdam!

Registrations are available at a reduced rate for ESCMID members on the official website.

Make sure you use our official website to book your hotels to get the best rates.

› Read more
OPEN CALLS | APPLICATIONS

Pre-ECCMID Machine Learning for Microbiology Workshop

Complement your ECCMID 2019 experience with the 'Machine Learning for Clinical Microbiology' the day before ECCMID in Amsterdam.

This workshop is happening on Friday, 12 April. Sign up using the ECCMID registration portal!

Limited places are available, the full day is only €100!

› Read more

IMMEM XII – Registration open

Registrations are now open for the 12th International Meeting on Microbial Epidemiological Markers (IMMEM XII), to be held in Dubrovnik, Croatia from  18-21 September.

In this edition of IMMEM, an expert faculty will discuss trends and changes in molecular typing techniques, and their impact on microbial typing and prediction of resistance. Comparisons will also be made between identification of individual microorganisms and microbiome characterisation.

View the programme, register and submit your abstract at the conference website

› Read more
 

CMI highlight: Comparison of five methods for detection of carbapenemases in Enterobacterales with proposal of a new algorithm

Baeza et al., Evaluate the performance of five different carbapenemase assays and develop an algorithm that will detect the most common and rare carbapenemases in routine microbiology laboratories.
The immunochromatographic tests CARBA-5 (NG), RESIST-4 O.K.N.V. (Coris), the colorimetric β-CARBA (BioRad), a newly developed carbapenem-inactivation method (CIM) supplemented with zinc (zCIM) and the Xpert Carba-R (Cepheid) were challenged with a collection of 189 molecularly characterized Enterobacterales isolates, including 146 carbapenemase producers (CPE): VIM (n=48), OXA-48-like (n=40), NDM (n=29), KPC (n=13), IMI (n=9), IMP (n=9), OXA-58 (n=2) and GES (n=2).
The overall sensitivity/specificity values for the five carbapenemase detection tests were 84.2%(CI 77.6%-89.2%)/100%(CI 91.8%-100%) for RESIST-4, 88.2%(CI 82.1%-92.4%)/100%(CI 91.8%-100%) for CARBA-5, 88.2%(CI 82.1%-92.4%)/100%(CI 91.8%-100%) for Xpert Carba-R, 73.7%(CI 66.2%-80.0%)/100%(CI 93.4%-99.0%) for β-CARBA and 97.4%(CI 87.9%-99.6%)/97.7%(CI 87.9%-99.6%) for zCIM. The four common carbapenemases (KPC, OXA-48-like, NDM and VIM) were detected with ≥97.6% sensitivity by all tests except for β-CARBA (76.6%[CI 68.4%-83.2%]). IMI and GES were only detected by zCIM (sensitivity 90.9%[CI 62.3%-98.4%]). Based on these results a new algorithm was developed, consisting of an immunochromatographic assay as the first test followed by zCIM, which allows detection of 99.3% of all evaluated carbapenemases.
With the exception of β-CARBA, all methods showed excellent sensitivity / specificity for detection of the four most common carbapenemases. With the new algorithm, rare variants can also be detected. It is fast, simple and inexpensive and can be performed in any microbiology laboratory, no PCR equipment is required.

› Read more
 

EUCIC Local Module – Bergamo, Italy

Don’t miss out on the upcoming EUCIC local module on Healthcare Associated Infections in Bergamo, Italy.

An expert faculty of experts from across Italy and Europe will address practical aspects of controlling HCAI’s in an interactive, engaging meeting.

Find out more at the EUCIC Local Modules Page

› Read more
 

GARDP Webinar – Clinical development for non-developers

Part 3 of GARDP’s series on Antibacterial drugs is occurring on Thursday!

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this webinar, the development of antibacterial drug enhancer combinations and non-traditional products will be discussed.

The presentations will be followed by a Q&A session.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.